-
AstraZeneca on Tuesday laid out an ambitious plan to boost growth in its existing oncology，biopharma and rare disease portfolios，as well as launch20new medicines before the end of the decade。
-
The regulator on Monday approved two interchangeable biosimilars to Regeneron’s Eylea，providing additional competition for the pharma’s blockbuster as key patent protections are set to expire。
-
Eli Lilly is paying$60 million upfront to Aktis Oncology to discover and develop novel tumor-targeting radiopharmaceuticals，as radiopharma dealmaking continues to heat up in 2024。
-
Late-stage results from the NOTUS trial showed Sanofi and Regeneron’s Dupixent lowered moderate to severe chronic obstructive pulmonary disease exacerbations by34%and led to significantly better lung function。
-
Participants experienced fewer asthma attacks when receiving the antibody every six months，GSK said Tuesday，positioning the company to file for approval of the potential blockbuster。
-
Formerly known as AbGenomics Holding，AltruBio on Tuesday said it will use the funds to push its ulcerative colitis asset into a Phase IIIIb trial with an anticipated readout in 2026。
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs。
-
Following its recent about-face on the BIOSECURE Act，designed to combat China’s influence in the biopharma industry，lobbying group Biotechnology Innovation Organization in a realignment is laying off30employees。
-
5/21/2024
Aligos Therapeutics，Inc.today announced that it has completed enrollment in the ALG-055009 Phase2a HERALD study for metabolic dysfunction-associated steatohepatititis（MASH）with topline safety and efficacy data anticipated in early Q4 2024。
-
5/21/2024
According to latest study，the U.S.mRNA therapeutics market size was worth around USD5.10billion in 2023and is predicted to grow around USD12.18billion by2033with a compound annual growth rate（CAGR）of roughly9.1%between 2024and2033。
-
5/21/2024
iLeadBMS，aleading biotech company dedicated to the discovery and development of novel drugs for high unmet medical needs，has announced a positive outcome of IL1512，a first-in-class CXCR7agonist，asa potential therapy for pulmonary fibrotic diseases
-
5/21/2024
ACG Engineering，a division of ACG，the world'sonly integrated pharmaceutical solutions and manufacturing company
-
5/21/2024
Brainomix，apioneer in artificial intelligence（AI）imaging solutions to enable precision medicine，is proud to announce the FDA clearance of its latest product
-
5/21/2024
车辆行驶状况，车辆行驶状况，车辆行驶状况，车辆行驶状况
-
5/21/2024
Brainomix，apioneer in artificial intelligence（AI）imaging solutions to enable precision medicine，announced a series of new studies that were presented this week at the European Stroke Organisation Conference
-
5/21/2024
cancer treatment has progressed remarkably over the preceding decennium with the advent of multiple novel treatments that involves the combinations of antibodies for the treatment of different types of cancer across the globe
-
5/21/2024
Delta-like ligand3（DLL3）has emerged asan exciting target for precision cancer medicine。DLL3is a protein expressed during fetal development that is involved in regulating cell differentiation。
-
5/21/2024
Vabysmo is emerging as significant player in the pharmaceutical landscape，particularly within the ophthalmology sector。
-
5/21/2024
Bionano Genomics today announced the publication of three studies which collectively illustrate the continued development of data supporting the utility of optical genome mapping（OGM）in cell and gene therapy applications。
-
5/21/2024
Provectus Biopharmaceuticals，Inc.announced posters were presented at the annual meeting of the Society for Investigative Dermatology（“SID”），held May15-182024in Dallas，Texas。
